(Information sent by the signatory company)
LONDON and FRANKFURT, Germany, Jan. 9, 2023 /PRNewswire/ -- Huma Therapeutics Limited ("Huma"), a leading global digital health company, today announced that it has acquired Alcedis GmbH ("Alcedis"), a market-leader for data driven clinical research and technology. Through the acquisition, Huma will form an advanced clinical trials division offering digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully decentralized trials.
Integrating Alcedis' clinical and operational know-how with Huma's digital expertise will make Huma the optimal healthtech provider, able to support the seamless integration of digital technology into clinical trials.
Headquartered in Germany, Alcedis has more than 25 years of clinical trial experience. Huma's award-winning technologies have been deployed since 2011. Between them, Huma and Alcedis have managed nearly a thousand studies across a wide range of therapeutic areas, including rare diseases, oncology, immunology, cardiovascular, respiratory, neurodegenerative, musculoskeletal, dermatology and metabolic diseases, in over 60 countries involving more than 650,000 participants.
Dan Vahdat, CEO
Hanno Härtlein, Managing Director Alcedis, said: "We are excited to be joining the Huma family, bringing our clinical trials expertise and capabilities to combine with those of Huma's award-winning technology-platform. Together, we will offer substantially greater benefit to pharmaceutical, medtech, clinical research organisation, and academic partners for their research projects."
Jeanne Kehren, Senior Vice President, Digital
Watch Dan and Hanno discuss the potential of the acquisition.
Financial terms are not disclosed.
About them
Huma Therapeutics is a global digital health technology company that advances digital-first care delivery and research to help people live longer, fuller lives.
Huma's award-winning modular platforms are used by more than 3,000 hospitals and clinics, with 1.8 million active users in healthcare and 650,000 participants across research. Huma's regulated Software as a Medical Device powers:
Huma's Decentralized and Hybrid Clinical Trial (DCT) platform now includes the clinical expertise of Alcedis GmbH, a global digital first clinical trials company and market-leader for data driven clinical research and technology.
Please visit www.huma.com and follow us on LinkedIn at Huma
Media contacts
Sian JarvisChief Corporate Affairs and Marketing Officer, Humasian.jarvis@huma.com
Karen Birmingham PhDHead of PR
Logo: https://mma.prnewswire.com/media/1427908...
View original content: https://www.prnewswire.co.uk/news-releases/huma-to-provide-best-in-class-digital-clinical-trials-solutions-through-landmark-acquisition-of-alcedis-301715943.html
